JP2025511382A - 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン - Google Patents

抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン Download PDF

Info

Publication number
JP2025511382A
JP2025511382A JP2024559004A JP2024559004A JP2025511382A JP 2025511382 A JP2025511382 A JP 2025511382A JP 2024559004 A JP2024559004 A JP 2024559004A JP 2024559004 A JP2024559004 A JP 2024559004A JP 2025511382 A JP2025511382 A JP 2025511382A
Authority
JP
Japan
Prior art keywords
antibody
subject
ivig
dose
clovalimab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511382A5 (https=
Inventor
ブアトワ，シモン・ベルトラン・マリー
圭介 五反田
賢治 四宮
ソステリー，アレクサンドル・アントワーヌ・ベルナール
ソウブレト，アントワーヌ・パウル・マクセンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2025511382A publication Critical patent/JP2025511382A/ja
Publication of JP2025511382A5 publication Critical patent/JP2025511382A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024559004A 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン Pending JP2025511382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166585.4 2022-04-04
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (2)

Publication Number Publication Date
JP2025511382A true JP2025511382A (ja) 2025-04-15
JP2025511382A5 JP2025511382A5 (https=) 2026-04-02

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559004A Pending JP2025511382A (ja) 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
CN118974082A (zh) 2024-11-15
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
CA3251880A1 (en) 2023-10-12
AU2023249891A1 (en) 2024-08-08
AU2023249891A9 (en) 2024-08-15
TW202404632A (zh) 2024-02-01
KR20240168984A (ko) 2024-12-02
IL314751A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
KR20220044563A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20220356261A1 (en) Treatment for sjögren's syndrome
KR20250107839A (ko) 심혈관계 질환의 치료 방법
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
JP2025511382A (ja) 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン
JP7798763B2 (ja) Ｃ５関連疾患の治療または予防のための投与レジメン
US20250236661A1 (en) Dosage and administration regimen for the treatment or prevention of guillan-barre syndrome by the use of the anti-05 antibody crovalimab
EP4072672A1 (en) Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
TW202337913A (zh) 每週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
CN109641053A (zh) 给药方案
JP7739537B2 (ja) Ｆｖｉｉｉ模倣二重特異性抗体を２ヶ月に１回投与する方法
WO2025096435A1 (en) Treatment of complement-associated renal diseases
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
TW202345897A (zh) 每月投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
TW202345896A (zh) 每兩週投予一次ｆｖｉｉｉ模擬雙特異性抗體之方法
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260325